Roche said that its checkpoint antibody Tecentriq (atezolizumab) plus chemotherapy has shown positive results in a Phase 3 study of patients with previously untreated metastatic urothelial carcinoma compared with chemotherapy alone. The study, IMvigor130, is said to be the first positive outcome of an immunotherapy combination in this patient population.
